Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 1/2023

Open Access 22-11-2022 | Propranolol | Review

The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review

Authors: Alya M. Alhazmi, Mohammad A. Basendwh, Abdullah Ayman Aman, Mazen Dajam, Turki S. Aljuhani

Published in: Dermatology and Therapy | Issue 1/2023

Login to get access

Abstract

Introduction

Beta-blockers are proven to be safe and cost-effective agents in treating multiple dermatological conditions, which is why they are considered as an interesting and good alternative therapeutic agent by dermatologists. To our knowledge, there has been no comprehensive systematic review to date summarizing the role of both systemic and topical beta-blockers in dermatology.

Methods

In this systematic review, we aim to review recent and relevant published literature in order to provide a comprehensive evidence-based summary to inform dermatologists.

Results

An electronic-based literature search was carried out during October–December 2021 in the databases PubMed (MEDLINE), SCOPUS (EMBASE), and Cochrane Library. Furthermore, bibliographic sources were also reviewed for the selected articles. We followed The Preferred Reporting Items for Systematic Reviews and Meta-analyses 2020 (PRISMA) guidelines. We reviewed published literature about the role of beta-blockers in dermatology for the time period (January 2016 to December 2021).

Conclusions

A total of 126 publications were retrieved from different databases, of which 59 studies were finally included in our review after excluding non-eligible literature in accordance with our inclusion and exclusion criteria. The included articles consisted of meta-analyses, systematic reviews, clinical trials, retrospective and prospective cohort studies, case–control studies, case series, and case reports. In general, data in reviewed literature showed that both systemic and topical beta-blockers were reliable and safe therapeutic options in treating different dermatoses. Their effect has been studied as a mono-therapy, also as an adjuvant therapy combined with other current disease-specific therapeutic modalities such as lasers, radiation, chemotherapy, corticosteroids, or other beta-blockers options. Local and systemic adverse effects were mainly minor and non-significant.
Literature
1.
Léauté-Labrèze C, De La Roque ED, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–51.CrossRef
2.
Steinkraus V, Steinfath M, Körner C, Mensing H. Binding of beta-adrenergic receptors in human skin. J Invest Dermatol. 1992;98(4):475–80.CrossRef
3.
Pullar CE, Isseroff RR. ß2-adrenergic receptor activation delays dermal fibroblast-mediated contraction of collagen gels via a cAMP-dependent mechanism. Wound Repair Regen. 2005;13(4):405–11.CrossRef
4.
5.
Innervation and receptor profiles of the human apocrine (epitrichial) sweat gland: routes for intervention in bromhidrosis - Lindsay - 2008 - British Journal of Dermatology - Wiley Online Library [Internet]. [cited 2022 Jan 14]. Available from: https://​onlinelibrary.​wiley.​com/​doi/​abs/​https://​doi.​org/​10.​1111/​j.​1365-2133.​2008.​08740.​x
6.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372): n71.CrossRef
7.
Puspitasari GD, Prawitasari S. Combining topical therapy and bisoprolol on refractory venous ulcer. J Dermatol Venereol Aesthetic. 2020;1(2):84–94.
8.
Hajighasemi F, Mirshafiey A. Propranolol effect on proliferation and vascular endothelial growth factor secretion in human immunocompetent cells. J Clin Immunol Immunopathol Res. 2010;2(2):22–7.
9.
Williams NM, Vincent LT, Rodriguez GA, Nouri K. Antihypertensives and melanoma: an updated review. Pigment Cell Melanoma Res. 2020;33(6):806–13.CrossRef
10.
11.
Olsen GM, Hansen LM, Stefanko NS, Mathes E, Puttgen KB, Tollefson MM, et al. Evaluating the safety of oral propranolol therapy in patients with PHACE syndrome. JAMA Dermatol. 2020;156(2):186–90.CrossRef
12.
Bayart CB, Tamburro JE, Vidimos AT, Wang L, Golden AB. Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study. Pediatr Dermatol. 2017;34(4):413–21.CrossRef
13.
Gumina ME, Yan AC. Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas. Pediatr Dermatol. 2019;36(4):556–7.
14.
Frost S, Saddi V, Teng A, Mallitt KA, Adams S, Williamson B, et al. Propranolol’s effects on the sleep of infants with hemangiomas: a prospective pilot study. Pediatr Dermatol. 2021;38(2):371–7.CrossRef
15.
Li L, Wei L, Xu ZG, Ma L. No Increased risks associated with propranolol treatment for infantile hemangioma in preterm infants were identified at 3 years of age. Am J Clin Dermatol. 2019;20(2):289–93.CrossRef
16.
Wang X, Feng W, Zhao X, Liu Z, Dong L. The efficacy and safety of topical β-blockers in treating infantile hemangiomas: a meta-analysis including 11 randomized controlled trials. Dermatology. 2021;237(3):433–43.CrossRef
17.
Bly RA, Perkins J, Parikh SR. Can topical beta-blockers reduce the size of superficial infantile hemangiomas of the head and neck? Laryngoscope. 2017;127(1):4–5.CrossRef
18.
Novoa M, Baselga E, Beltran S, Giraldo L, Shahbaz A, Pardo-Hernandez H, et al. Interventions for infantile haemangiomas of the skin: abridged Cochrane systematic review and GRADE assessments. Br J Dermatol. 2019;180(3):527–33.CrossRef
19.
Chen X, Guo Y, Wang P, Qiu F, Sun Y, Shi Q, et al. Efficacy and safety of adrenergic beta-antagonist combined with lasers in the treatment of infantile hemangiomas: a meta-analysis. Pediatr Surg Int. 2020;36(10):1135–47.CrossRef
20.
Mashiah J, Hadj-Rabia S, Slodownik D, Harel A, Sprecher E, Kutz A. Effectiveness of topical propranolol 4% gel in the treatment of pyogenic granuloma in children. J Dermatol. 2019;46(3):245–8.CrossRef
21.
El-Taweel AEAI, Al-Refaie AAASA, Salem KHA, Salem RM. Topical β-blockers for pyogenic granulomas: a promising option for younger patients. J Cosmet Dermatol. 2021;20(6):1801–6.CrossRef
22.
Sollena P, Mannino M, Tassone F, Calegari MA, D’Argento E, Peris K. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. Drugs Context. 2019;6(8): 212613.
23.
Al Mokadem SM, Ibrahim ASM, El Sayed AM. Efficacy of topical timolol 0.5% in the treatment of acne and rosacea: a multicentric study. J Clin Aesthetic Dermatol. 2020;13(3):22–7.
24.
Logger JGM, Olydam JI, Driessen RJB. Use of beta-blockers for rosacea-associated facial erythema and flushing: a systematic review and update on proposed mode of action. J Am Acad Dermatol. 2020;83(4):1088–97.CrossRef
25.
De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E, et al. Propranolol for off-label treatment of patients with melanoma. JAMA Oncol. 2018;4(2): e172908.CrossRef
26.
27.
Katsarelias D, Eriksson H, Mikiver R, Krakowski I, Nilsson JA, Ny L, et al. The effect of beta-adrenergic blocking agents in cutaneous melanoma-a nation-wide Swedish population-based retrospective register study. Cancers. 2020;12(11):E3228.CrossRef
28.
Afra TP, De D. Topical timolol for postacne erythema. J Am Acad Dermatol. 2021;84(6):e255–6.CrossRef
29.
Kimwattananukul K, Noppakun N, Asawanonda P, Kumtornrut C. Topical 0.5% timolol maleate significantly enhances skin-barrier restoration after fractional carbon dioxide laser treatment for acne scars. Lasers Surg Med. 2021;53(5):610–5.CrossRef
30.
Enoshiri T, Naitoh M, Yamawaki S, Kawaguchi A, Aya R, Noda K, et al. β-adrenergic receptor blockers reduce the occurrence of keloids and hypertrophic scars after cardiac device implantation: a single-institution case–control study. Plast Reconstr Surg. 2017;139(5):1248–56.CrossRef
31.
32.
Dabiri G, Tiger J, Goreshi R, Fischer A, Iwamoto S. Topical timolol may improve overall scar cosmesis in acute surgical wounds. Cutis. 2017;100(1):E27–8.
33.
Vestita M, Bonamonte D, Filoni A. Topical propranolol for a chronic recalcitrant wound: topical propranolol for a chronic recalcitrant wound. Dermatol Ther. 2016;29(3):148–9.CrossRef
34.
Vestita M, Filoni A, Bonamonte D, Annoscia P, Giudice G. Abstract: topical 0.5% timolol for chronic refractory wounds an observational prospective study. Plast Reconstr Surg Glob Open. 2017;5(9):21.CrossRef
35.
Rai AK, Janani K, Rai R. Efficacy of topical timolol versus saline in chronic venous ulcers: a randomized controlled trial. J Cutan Aesthetic Surg. 2020;13(1):18–23.
36.
Pawar M. Topical timolol in chronic, recalcitrant fissures and erosions of hand eczema. J Am Acad Dermatol. 2021;84(3):e125–6.CrossRef
37.
Pawar MK. Treatment of painful and deep fissures of the heel with topical timolol. J Am Acad Dermatol. 2021;85(1):e3-4.CrossRef
38.
Li YF, Chen XY, Lei TC. Inhibitory effect of timolol on topical glucocorticoid-induced skin telangiectasia. Mol Med Rep. 2018;18(3):2823–31.CrossRef
39.
Abdelmaksoud A, Filoni A, Giudice G, Vestita M. Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel. J Am Acad Dermatol. 2017;76(1):153–5.CrossRef
40.
41.
Farshchian M, Potts GA. Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma. Australas J Dermatol. 2021;62(4):e580–1.CrossRef
42.
Hartmann F, Lockmann A, Himpel O, Kühnle I, Hensen J, Schön MP, et al. Combination therapy of oral propranolol and combined Nd:YAG/pulsed dye laser therapy in infantile hemangiomas: a retrospective analysis of 48 treated hemangiomas in 30 children. JDDG J Dtsch Dermatol Ges. 2020;18(9):984–93.
43.
Chaturvedi K, Steinberg JS, Snyder CS. Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting. Cardiol Young. 2018;28(10):1105–8.CrossRef
44.
Putterman E, Wan J, Streicher JL, Yan AC. Evaluation of a modified outpatient model for using propranolol to treat infantile hemangiomas. Pediatr Dermatol. 2019;36(4):471–6.
45.
Frongia G, Byeon JO, Arnold R, Mehrabi A, Günther P. Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants. World J Pediatr WJP. 2018;14(3):254–8.CrossRef
46.
Shi H, Song H, Wang J, Xia L, Yang J, Shang Y, et al. Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. Ultrasound Med Biol. 2014;40(11):2622–9.CrossRef
47.
Kagami S, Kaneko M, Kishi A, Katori T. Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. J Dermatol. 2018;45(9):1109–12.CrossRef
48.
Filoni A, Ambrogio F, De Marco A, Pacifico A, Bonamonte D. Topical beta-blockers in dermatologic therapy. Dermatol Ther. 2021;34(4): e15016.CrossRef
49.
Prabha N, Chhabra N, Arora R. Beta-blockers in dermatology. Indian J Dermatol Venereol Leprol. 2017;83(3):399–407.CrossRef
50.
Chen L, Tsai TF. The role of β-blockers in dermatological treatment: a review. J Eur Acad Dermatol Venereol JEADV. 2018;32(3):363–71.CrossRef
51.
Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebbé G, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138(4): e20160353.CrossRef
52.
Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet Lond Engl. 2017;390(10089):85–94.CrossRef
53.
Mellerio JE. Beta blockers for infantile haemangiomas: where should we go from here? Br J Dermatol. 2019;180(3):450–1.CrossRef
54.
Al-Haddad C, El Salloukh NA, El Moussawi Z. β-blockers in the treatment of periocular infantile hemangioma. Curr Opin Ophthalmol. 2019;30(5):319–25.CrossRef
55.
Oberlin KE. Expanding uses of propranolol in dermatology. Cutis. 2017;99(4):E17–9.
56.
Kim KH, Choi TH, Choi Y, Park YW, Hong KY, Kim DY, et al. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. JAMA Dermatol. 2017;153(6):529–36.CrossRef
57.
Hu L, Zhou B, Huang H, Chang L, Qiu Y, Ma G, et al. Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas. J Dermatol. 2016;43(10):1160–6.CrossRef
58.
Zaher H, Rasheed H, El-Komy MM, Hegazy RA, Gawdat HI, Abdel Halim DM, et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): a randomized controlled trial. J Am Acad Dermatol. 2016;74(3):499–505.CrossRef
59.
Baselga E, Dembowska-Baginska B, Przewratil P, González-Enseñat MA, Wyrzykowski D, Torrelo A, et al. Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma. Pediatrics. 2018;142(3): e20173866.CrossRef
60.
Kagami S, Kaneko M, Katori T. Thirty-two Japanese cases of infantile hemangiomas treated with oral propranolol. J Dermatol. 2018;45(6):719–22.CrossRef
61.
Kaneko T, Sasaki S, Baba N, Koh K, Matsui K, Ohjimi H, et al. Efficacy and safety of oral propranolol for infantile hemangioma in Japan. Pediatr Int Off J Jpn Pediatr Soc. 2017;59(8):869–77.CrossRef
62.
63.
Lahrichi A, Hali F, Baline K, Fatoiki FZE, Chiheb S, Khadir K. Effects of propranolol therapy in Moroccan children with infantile hemangioma. Arch Pediatr Organe Off Soc Francaise Pediatr. 2018;25(8):449–51.
64.
Tan JMC, Lim HW, Koh MJA. Oral propranolol for the treatment of infantile haemangiomas in Singapore. Singapore Med J. 2021;62(3):139–42.CrossRef
65.
Treatment with propranolol for infantile hemangiomas: single‐center experience—Turhan. J Cosmet Dermatol Wiley Online Library 2016 [Internet]. [cited 2021 Nov 10]. Available from: https://​onlinelibrary.​wiley.​com/​doi/​abs/​https://​doi.​org/​10.​1111/​jocd.​12220
66.
Tognetti L, Pianigiani E, Ierardi F, Cartocci A, Fiorani D, de Quattro M, et al. A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. Dermatol Ther. 2020;33(6): e14283.CrossRef
67.
Schwartz T, Faria J, Pawar S, Siegel D, Chun RH. Efficacy and rebound rates in propranolol-treated subglottic hemangioma: a literature review. Laryngoscope. 2017;127(11):2665–72.CrossRef
68.
Mannschreck DB, Huang AH, Lie E, Psoter K, Puttgen K. Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2019;36(3):283–9.CrossRef
69.
70.
Yu X, Zhang J, Wu Z, Liu M, Chen R, Gu Y, et al. LUMBAR syndrome: A case manifesting as cutaneous infantile hemangiomas of the lower extremity, perineum and gluteal region, and a review of published work. J Dermatol. 2017;44(7):808–12.CrossRef
71.
Seo BH, Kim DH, Suh HS, Choi YS. Facial flushing and erythema of rosacea improved by carvedilol. Dermatol Ther. 2020;33(6): e14520.CrossRef
72.
De Giorgi V, Grazzini M, Benemei S, Marchionni N, Geppetti P, Gandini S. β-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up. Melanoma Res. 2017;27(3):268–70.CrossRef
73.
74.
Khan M, Boyce A, Prieto-Merino D, Svensson Å, Wedgeworth E, Flohr C. The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis. Acta Derm Venereol. 2017;97(10):1167–71.CrossRef
75.
Chen QY, Chang L, Qiu YJ, Ying HR, Chang SJ, Zhang Y, et al. Comparison of the efficacy between topical timolol and pulsed dye laser in the treatment of ulcerated infantile haemangiomas: a randomized controlled study. J Eur Acad Dermatol Venereol JEADV. 2021;35(4):e303–5.CrossRef
76.
Ying H, Zou Y, Yu W, Qiu Y, Ma G, Chang L, et al. Prospective, open-label, rater-blinded and self-controlled pilot study of the treatment of proliferating superficial infantile hemangiomas with 0.5% topical timolol cream versus 595-nm pulsed dye laser. J Dermatol. 2017;44(6):660–5.CrossRef
77.
Gan LQ, Wang H, Ni SL, Tan CH. A prospective study of topical carteolol therapy in Chinese infants with superficial infantile hemangioma. Pediatr Dermatol. 2018;35(1):121–5.CrossRef
78.
Mashiah J, Kutz A, Rabia SH, Ilan EB, Goldberg I, Sprecher E, et al. Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. Int J Dermatol. 2017;56(2):148–53.CrossRef
79.
Neri I, Baraldi C, Balestri R, Piraccini BM, Patrizi A. Topical 1% propranolol ointment with occlusion in treatment of pyogenic granulomas: an open-label study in 22 children. Pediatr Dermatol. 2018;35(1):117–20.CrossRef
Metadata
Title
The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review
Authors
Alya M. Alhazmi
Mohammad A. Basendwh
Abdullah Ayman Aman
Mazen Dajam
Turki S. Aljuhani
Publication date
22-11-2022
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 1/2023
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-022-00848-1

Other articles of this Issue 1/2023

Dermatology and Therapy 1/2023 Go to the issue

Commentary

Commentary: Facial Aesthetic Dermatological Procedures and Photoprotection in Chinese Populations

Original Research

Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data

Original Research

Application of Comfort Therapy under eCASH Concept in Acute and Chronic Wound Treatment

Letter

Letter to the Editor Regarding a Comprehensive Update of the Atypical, Rare, and Mimicking Presentations of Mycosis Fungoides

Original Research

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study

Commentary

Allergic to Fashion

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits